: iStockAnalyst.com Symbols Feed

DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments

Fri, 14 Aug 2009 11:56:00 GMT

DOR BioPharma, Inc. , a late-stage biopharmaceutical company, today announced its financial results for the second quarter of 2009.[More...]

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

Tue, 04 Aug 2009 10:56:00 GMT

DOR BioPharma, Inc., , a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration has granted Orphan Drug Designation to Oral BDP )) for the treatment of gastrointestinal symptoms associated with chronic Graft-versus-Host disease in patients who have undergone allogeneic hematopoietic cell transplantation.[More...]

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

Wed, 08 Jul 2009 11:56:00 GMT

DOR BioPharma, Inc. , a late-stage biopharmaceutical company, announced today that it has received a European patent which addresses its Lipid Polymer Micelle ) technology for the improved oral delivery of drugs. The issued European patent, EP 1460992, entitled "Stabilized Reverse Micelle Compositions and Uses Thereof" covers lipid structures that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.[More...]

DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller

Tue, 07 Jul 2009 11:57:00 GMT

DOR BioPharma, Inc. , a late-stage biopharmaceutical company, announced today that it recently appointed Christopher P. Schnittker, CPA as its new Vice President of Administration and Controller. In this role, Mr. Schnittker will oversee the Accounting, Human Resources, and Administrative functions, as well as serve as the Company's Principal Accounting Officer for SEC reporting purposes.[More...]

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

Tue, 09 Jun 2009 10:56:00 GMT

DOR BioPharma, Inc. , a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency on the design of its confirmatory, pivotal, Phase 3 clinical trial evaluating its lead product orBec for the treatment of acute gastrointestinal Graft-versus-Host Disease .[More...]

DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments

Fri, 15 May 2009 11:56:00 GMT

DOR BioPharma, Inc. , a late-stage biopharmaceutical company, today announced its financial results for the first quarter of 2009.[More...]

Life Science Leaders to Discuss Finding Investors in a Tough Economy

Thu, 07 May 2009 14:57:00 GMT

WHAT: Join regional life science and investment executives for an analysis of the challenges facing the biotechnology sector in the wake of the lingering financial crisis.
Ernst & Young, in its annual report on the biotechnology sector, just Tuesday declared the present biotechnology business model "unsustainable."
WHO: Yankee PR President Fred Feiner will moderate three panels focused on successful finance strategies, the current investment market and regulatory tactics to maximize profitability.

[More...]

DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments

Tue, 31 Mar 2009 11:59:00 GMT

DOR BioPharma, Inc. , a late-stage biopharmaceutical company, today announced its financial results for 2008.[More...]

DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation

Wed, 25 Mar 2009 10:57:00 GMT

DOR BioPharma, Inc. , a late-stage biopharmaceutical company, announced today that it has entered into a $400,000 common stock equity investment agreement priced at market with its clinical trials management partner, Numoda Corporation . One hundred thousand dollars of this investment will be completed in January 2010. This investment follows and enhances the collaboration between DOR and Numoda announced June 30, 2008 and represents partial payment by DOR under the collaboration agreement.[More...]

DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors

Mon, 16 Mar 2009 11:10:00 GMT

DOR BioPharma, Inc. announced today that it has appointed Gregg Lapointe, CPA, MBA, to its Board of Directors. Mr. Lapointe is currently Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc. , a company dedicated to the development and commercialization of medicines for patients with rare diseases. Sigma-Tau is DOR's North American partner for orBec and its largest shareholder.[More...]